[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Corxel Pharmaceuticals\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":110},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,80],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100642183","phase-1-a-study-to-evaluate-the-safety-and-tolerability-of-different-doses-of-cx11-tablets-100642183",false,"NCT07652047","A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets","A Phase 1b Study Investigating Safety, Pharmacokinetics, and Pharmacodynamics of CX11 Tablets in Participants With Obesity or Overweight With Weight-Related Comorbidities","Inclusion Criteria:\n\n* Male or female, 18-55 years.\n* BMI ≥30.0 to ≤39.9 kg\u002Fm², or ≥27.0 to \\\u003C30.0 kg\u002Fm² with at least 1 weight-related comorbidity: prediabetes, hypertension, dyslipidemia, or obstructive sleep apnea.\n* Prior unsuccessful diet\u002Fexercise weight-loss attempt and stable body weight within 90 days.\n* Able to comply with study procedures and reproductive requirements.\n\nExclusion Criteria:\n\n* Diabetes or obesity due to endocrine\u002Fgenetic causes.\n* Recent weight-loss drugs, GLP-1-based therapy, glucose-lowering drugs, obesity surgery\u002Fdevice, or investigational treatment.\n* Significant cardiovascular, ECG\u002FQT, pancreatic, gallbladder, GI, liver, kidney, thyroid, psychiatric, malignant, infectious, autoimmune, or lab abnormality risks.\n* Personal\u002Ffamily history of medullary thyroid carcinoma or multiple endocrine neoplasia.\n* Pregnancy, breastfeeding, recent nicotine\u002Fdrug use, excessive alcohol use, or any condition\u002Fmedication making participation inappropriate.","FEMALE","18 Years","55 Years",{"count":20,"type":21},90,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","A multi-center, randomized, placebo-controlled, double-blinded (within cohorts), Sponsor-unblinded, Phase 1b study to explore the safety, pharmacokinetics, and pharmacodynamics of CX11 tablets in participants with obesity or overweight with weight-related comorbidities.",[27],"Obesity & Overweight","RECRUITING","2026-06-15",{"date":31,"type":32},"2026-06-17","ACTUAL",{"date":34,"type":32},"2026-05-11",{"date":36,"type":21},"2027-06",{"name":38,"class":39},"Corxel Pharmaceuticals","INDUSTRY",2,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":48,"minAge":17,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},"100619107","phase-2-a-study-of-cx11-tablets-in-patients-with-type-2-diabetes-mellitus-100619107","NCT07340320","A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Finding Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus","Inclusion Criteria\n\nParticipants who meet all of the following criteria will be eligible to participate in this study:\n\n* Adults aged 18 to 75.\n* Diagnosis of type 2 diabetes for at least 6 months.\n* HbA1c between 7.0% and 10.5%.\n* Body mass index (BMI) between 23 and 50 kg\u002Fm².\n* Body weight stable for the past 3 months before joining.\n* Stable dose of metformin (≥1000 mg\u002Fday), with or without SGLT2i, for ≥3 months.\n* Women of childbearing potential (WOCBP): highly effective contraception ≥6 months prior to screening, throughout study, and 90 days post-last dose; negative pregnancy test within 24 hrs of first dose; no intent to donate sperm\u002Fova\n* Agrees to avoid grapefruit\u002Fgrapefruit products\n\nExclusion Criteria\n\nParticipants who meet any of the following criteria will be excluded from this study:\n\n* Anticipated initiation or change in concomitant medications (for more than 14 consecutive days) known to affect weight or glucose metabolism (e.g. treatment with orlistat, thyroid hormones, or systemic corticosteroids).\n* Type 1 diabetes or a history of diabetic ketoacidosis.\n* Use of any GLP-1 receptor agonist within the past 6 months, or any prior exposure to CX11.\n* Use of insulin to control blood sugar within the past 12 months.\n* More than one episode of severe low blood sugar, with awareness of hypoglycemia symptoms.\n* Cardiovascular or cerebrovascular conditions within the past 6 months:\n\n  * Heart attack, coronary angioplasty, or bypass surgery (diagnostic angiography allowed).\n  * Valvular heart disease or prior heart valve repair surgery.\n  * Unstable angina.\n  * Transient ischemic attack (TIA) or stroke.\n  * Decompensated heart failure (NYHA Class III or IV).\n  * ECG abnormalities indicating significant safety risk, such as supraventricular tachycardia, torsades de pointes, second- or third-degree AV block, myocardial infarction, QTcF \\> 450 ms in males or \\> 470 ms in females, PR interval \\> 220 ms.\n  * Poorly controlled hypertension at screening: systolic ≥ 180 mmHg or diastolic ≥ 100 mmHg.\n* Pancreatic or gallbladder conditions:\n\n  * Acute or chronic pancreatitis.\n  * Symptomatic gallbladder disease (previous cholecystectomy is allowed).\n  * Pancreatic injury or risk factors that increase pancreatitis risk.\n* Thyroid conditions:\n\n  * Poorly controlled abnormal thyroid function on a stable dose before screening.\n  * Clinically significant abnormal thyroid test results at screening.\n  * Personal or first-degree family history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) type 2A or 2B.\n* Cancer history:\n\n  * Malignancy within the past 5 years, regardless of recurrence or metastasis. Exceptions: localized basal cell skin cancer, low-risk prostate cancer, cervical carcinoma in situ, or high-grade prostatic intraepithelial neoplasia.\n* Gastrointestinal conditions or treatments that may affect drug absorption:\n\n  * Abnormal gastric emptying (e.g., gastric outlet obstruction).\n  * Severe chronic gastrointestinal disease, including active ulcer within 6 months.\n  * Crohn's disease, ulcerative colitis, or other inflammatory bowel diseases.\n  * Prior gastrointestinal surgery (except polypectomy and appendectomy).\n  * Long-term use of drugs that directly affect gastrointestinal motility (e.g., mosapride, cisapride).\n* Liver disease:\n\n  * Active liver disease other than nonalcoholic fatty liver.\n  * Chronic active hepatitis B or C.\n  * Primary biliary cirrhosis.\n* Eye disease:\n\n  * Uncontrolled or potentially unstable diabetic retinopathy or maculopathy.\n* Abnormal lab results at screening:\n\n  * eGFR \\\u003C 60 mL\u002Fmin\u002F1.73 m² (CKD-EPI).\n  * ALT or AST \\> 2.5 × upper limit of normal (ULN).\n  * Total bilirubin \\> 1.5 × ULN (except known Gilbert's syndrome).\n  * Serum amylase or lipase \\> 1.5 × ULN.\n  * Fasting triglycerides \\> 5.7 mmol\u002FL.\n  * TSH \\> 1.5 × ULN or \\\u003C 1.0 × LLN.\n  * Calcitonin ≥ 20 ng\u002FL.\n  * Hemoglobin \\\u003C 110 g\u002FL (male) or \\\u003C 100 g\u002FL (female).","ALL","75 Years",{"count":51,"type":21},240,[53],"PHASE2","This study is testing whether a new medication called CX11 works and is safe for participants with type 2 diabetes who have not reached good blood sugar control while taking a steady dose of metformin, with or without a steady dose of an SGLT2 inhibitor, for at least 90 days.\n\nThe study is being done at multiple medical centers. Participants are assigned by chance (randomized) to different groups, and neither the participants nor the study staff know which group they're in (double-blind). The groups are compared side by side (parallel), and some participants will receive inactive pills (placebo) to help measure the true effect of the study drug.\n\nAfter screening, participants will be randomly placed into one of six groups, with equal chances of being in any group. Each group will receive a different dose of CX11 or a placebo. Treatment will last 24 weeks. After that, all participants will have a 2-week follow-up period to check on safety.",[56],"Type II Diabetes Mellitus",[58,59,60,61,62,63,64,65,66,67,68,69,70],"Type 2 Diabetes Mellitus","HbA1C","Percentage change in HbA1C","Change in Fasting Plasma Glucose","Change in body weight","Body weight loss","Hypoglycemics episodes","Hypoglycemia","Continuous Glucose Monitoring","Blood glucose","Health Survey Short Form-36","Diabetes treatment satisfaction questionnaire","Columbia-suicide severity rating scale","2026-05-26",{"date":73,"type":32},"2026-05-28",{"date":75,"type":32},"2026-02-06",{"date":77,"type":21},"2027-01-07",{"name":38,"class":39},45,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":48,"minAge":17,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":91,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},"100592241","phase-2-optimizing-reperfusion-to-improve-outcomes-and-neurologic-function-100592241","NCT06990867","Optimizing Reperfusion to Improve Outcomes and Neurologic Function","Optimizing Reperfusion to Improve Outcomes and Neurologic Function (ORION): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Phase 2\u002F3 Study to Evaluate the Efficacy and Safety of JX10 in Acute Ischemic Stroke With Late Presentations","ORION","Inclusion Criteria:\n\n1. Age ≥ 18 and ≤ 90 years old.\n2. Acute ischemic stroke with compatible clinical presentation and symptomatic high grade or complete occlusion of the intracranial internal carotid, M1, M2 or distal branches of the middle cerebral artery (MCA), anterior cerebral artery (ACA), or posterior cerebral artery (PCA).\n3. Radiographic evidence of salvageable tissue.\n4. Pre-treatment score of NIHSS ≥ 5.\n\nExclusion Criteria:\n\n1. Radiographic findings pre-randomization of any of the following:\n\n   1. Large core infarction, or\n   2. Occlusion in more than 1 vascular territory, or\n   3. Significant mass effect or clinically significant cerebral edema, or\n   4. Evidence of acute intracranial or extracranial hemorrhage, intracranial tumor (except small meningioma), neoplasm, or arteriovenous malformation), or\n   5. Clinical history, past imaging, or clinical judgement suggests that the intracranial occlusion is chronic.\n2. Medical history or active clinically significant bleeding, lesions, or conditions (at the investigator's judgement) considered to be of significant risk for major bleeding.\n3. Severe, uncontrolled hypertension (systolic blood pressure ≥ 185 mmHg or diastolic blood pressure ≥ 110 mmHg) that cannot be controlled with antihypertensive therapy.\n4. Known bleeding diathesis (hereditary or acquired) or any significant coagulopathy. Specifically, platelet count \\\u003C 100,000\u002FμL, international normalized ratio \\> 1.7, aPTT \\> 40 seconds, or prothrombin time \\> 15 seconds.\n5. Major trauma, surgery, or invasive procedures.\n6. Pre-existing medical, neurological, or psychiatric disease that would confound the neurological or functional evaluations of this study.\n7. Pre-treatment blood glucose \\> 400 mg\u002FdL (22.20 mmol\u002FL) or Pre-treatment blood glucose \\\u003C 50 mg\u002FdL (2.78 mmol\u002FL) unless it is corrected prior to study treatment administration. Participants with subsequently normalized blood glucose levels may be considered for inclusion, per Investigator judgement.","90 Years",{"count":90,"type":21},740,[53,92],"PHASE3","The goal of this study is to evaluate the safety and efficacy of JX10 versus placebo in participants with Acute Ischemic Stroke (AIS) who present for care within 4.5 to 24 hours.\n\nThe main question the study aims to answer are:\n\n1. JX10 improves functional outcomes as measured by the modified Rankin Scale score when compared with placebo following AIS.\n2. Risk of symptomatic intracranial hemorrhage of JX10 in participants with AIS.\n\nDuring Part 1, participants will be randomized to JX 10 (1mg\u002Fkg, 3 mg\u002Fkg) or placebo. During Part 2, participants will receive JX10 (optimal dose chosen from Part 1) or placebo.",[95],"Acute Ischemic Stroke",[97,86,95,98,99,100],"reperfusion","Late Presentation","JX10","thrombolytic","2026-03-11",{"date":103,"type":32},"2026-03-13",{"date":105,"type":32},"2025-05-15",{"date":107,"type":21},"2029-12-31",{"name":38,"class":39},83,""]